Revenue grew 18% YoY to €49.6m, led by strong Derma and Gastro/CDMO segments, but operating loss widened to €6.6m due to higher expenses and lower project-based revenue. Winlevi expanded in Europe, and the pipeline advanced with key regulatory milestones.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.